Hoth Therapeutics Inc.
| NASDAQ: HOTH | Healthcare / Biotechnology / USA |
| 1.48 | -0.1002 | -6.34% | Vol 467.79K | 1Y Perf -51.72% |
| Apr 19th, 2021 11:48 DELAYED |
| BID | 1.47 | ASK | 1.49 | ||
| Open | 1.56 | Previous Close | 1.58 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 10.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 562.25 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Market Cap | 33.71M | Earnings Rating | Neutral | |
| Price Range Ratio 52W % | 0.57 | Earnings Date | 12th May 2021 |
Today's Price Range 1.461.60 | 52W Range 1.464.96 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -11.24% | ||
| 1 Month | -27.52% | ||
| 3 Months | -28.18% | ||
| 6 Months | -11.73% | ||
| 1 Year | -51.72% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -204.44 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -178.19 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -213.75 | |||
Return on invested Capital Q | -15.10 | |||
Return on invested Capital Y | -204.44 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -3.30 | ||||
| 9.39 | ||||
| - | ||||
| - | ||||
| -8.40 | ||||
| -0.50 | ||||
| 9.39 | ||||
| 0.20 | ||||
| 38.91M | ||||
| Forward PE | -4.56 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 15.00 | ||||
| 15.30 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2020 | -0.14 | -0.20 | -42.86 |
| Q01 2020 | -0.17 | -0.18 | -5.88 |
| Q03 2019 | -0.10 | -0.17 | -70.00 |
| Q02 2019 | - | -0.13 | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2020 FY | -0.60 | 0.00 | - |
| 3/2021 QR | -0.10 | - | - |
| 6/2021 QR | -0.14 | - | - |
| 12/2021 FY | -0.39 | - | - |
| Next Report Date | 12th May 2021 |
| Estimated EPS Next Report | -0.10 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 467.79K |
| Shares Outstanding | 22.78M |
| Trades Count | 1.42K |
| Dollar Volume | 8.21M |
| Avg. Volume | 3.61M |
| Avg. Weekly Volume | 1.46M |
| Avg. Monthly Volume | 5.39M |
| Avg. Quarterly Volume | 3.79M |
Hoth Therapeutics Inc. (NASDAQ: HOTH) stock closed at 1.58 per share at the end of the most recent trading day (a -3.66% change compared to the prior day closing price) with a volume of 1.20M shares and market capitalization of 33.71M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 2 people. Hoth Therapeutics Inc. CEO is Robb Knie.
The one-year performance of Hoth Therapeutics Inc. stock is -51.72%, while year-to-date (YTD) performance is -33.33%. HOTH stock has a five-year performance of %. Its 52-week range is between 1.46 and 4.96, which gives HOTH stock a 52-week price range ratio of 0.57%
Hoth Therapeutics Inc. currently has a PE ratio of -3.30, a price-to-book (PB) ratio of 9.39, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -178.19%, a ROC of -213.75% and a ROE of -204.44%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Hoth Therapeutics Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.10 for the next earnings report. Hoth Therapeutics Inc.’s next earnings report date is 12th May 2021.
The consensus rating of Wall Street analysts for Hoth Therapeutics Inc. is Strong Buy (1), with a target price of $10, which is +562.25% compared to the current price. The earnings rating for Hoth Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Hoth Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Hoth Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 31.43, ATR14 : 0.26, CCI20 : -138.80, Chaikin Money Flow : -0.52, MACD : -0.19, Money Flow Index : 15.26, ROC : -16.40, RSI : 36.43, STOCH (14,3) : 10.77, STOCH RSI : 0.00, UO : 31.77, Williams %R : -89.23), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Hoth Therapeutics Inc. in the last 12-months were: Anthony Hayes (Sold 800 000 shares of value $1 000 000 )
Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
CEO: Robb Knie
Telephone: +1 646 756-2997
Address: 1 Rockefeller Plaza, New York 10020, NY, US
Number of employees: 2
